克拉霉素联合舒利迭治疗咳嗽变异性哮喘的临床观察
Clinical Observation of the Effect of Clarithromycin Combined with Seretide in Treating Cough Variant Asthma
张锋 1李晓珍1
作者信息
- 1. 浙江省龙泉市人民医院呼吸内科,323700
- 折叠
摘要
目的:探讨克拉霉素联合舒利迭治疗咳嗽变异性哮喘(CVA)的临床疗效及可能机制.方法:纳入74例CVA病例并随机分成两组,分别使用舒利迭(对照组),克拉霉素联合舒利迭(实验组)各治疗3个月.比较治疗前后临床症状、第1秒用力呼气量占预计值百分比(FEV1%)、峰值呼气流速(PEF)的变异率、血清IgE水平以及外周血单核细胞NF-κB活性.结果:实验组临床疗效明显高于对照组,克拉霉素联合舒利迭能改善患者的FEV1%、PEF变异率,降低血清IgE水平以及外周血单核细胞NF-κB活性.结论:克拉霉素联合舒利迭治疗CVA,可能通过调节患者外周血中单核细胞NF-κB的活性,从而降低了血清IgE水平,减轻了气道高反应性,临床疗效确切.
Abstract
Objective To investigate the clinical effect and potential mechanism of clarithromycin combined with seretide in treating cough variant asthma (CVA). Methods A total of 74 patients with CVA were randomly divided into the control group (treated with seretide) and experimental group ( clarithromycin combined with seretide) and treated for three months separately. The clinical symptoms, forced expiratory volume in the first second(FEV1% ) , peak expiratory flow(PEF) variance and serum IgE level and NF-KB activity of monocytea in peripheral blood were compared before and after treatment. Results The clinical effect in the experimental group was obviously higher than that of the control group, which could improve FEV1% , PEF variance, reduce serum IgE level and NF-KB activity of monocytes in peripheral blood. Conclusion The combination of clarithromycin with seretide could reduce the serum IgE level by regulating the NF-KB activity of monocytes in peripheral blood, thus releasing the airway hyperresponsiveness with clear clinical efficacy.
关键词
克拉霉素/舒利迭/咳嗽变异性哮喘/核因子-κB/免疫球蛋白EKey words
larithromycin/seretide/cough variant asthma(CVA)/nuclear factor-κB(NF-ΚB)/IgE引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据